Trials / Active Not Recruiting
Active Not RecruitingNCT02194842
Phase III Radium 223 mCRPC-PEACE III
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 446 (actual)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in castration resistant prostate cancer (CRPC) patients metastatic to bone
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ra223 | |
| DRUG | Enzalutamide |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2024-02-19
- Completion
- 2028-12-01
- First posted
- 2014-07-18
- Last updated
- 2025-09-19
Locations
64 sites across 12 countries: Belgium, Brazil, Canada, Denmark, France, Ireland, Italy, Norway, Poland, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT02194842. Inclusion in this directory is not an endorsement.